HIGHLIGHTS
- who: Paul Baas from the Department of Thoracic Oncology, The Netherland Cancer Institute, Amsterdam, Netherlands, Department of Pulmonary and Thoracic Oncology, CHU, Lille, France University of Basel, Switzerland have published the research: Immunotherapy in Malignant Pleural Mesothelioma, in the Journal: (JOURNAL) of 21/02/2020
SUMMARY
Frontiers in Oncology | www.frontiersin.org Malignant pleural mesothelioma (MPM) is a rare, aggressive malignancy with limited treatment options. At this time, the only registered systemic treatment is platinum-based chemotherapy combined with pemetrexed, with or without bevacizumab. In both MESOT-TREM trials 29 patients with MPM . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.